Handling Considerations Specific to Four-Component Blends Multi-peptide blends introduce one quality-control consideration that single-component vials do not: the researcher cannot verify component identity from visual inspection or simple purity testing alone
Who Should NOT Consider Peptides Based on current evidence, I would advise against peptide use in the following individuals: Anyone with a current or recent cancer diagnosis Anyone with a strong family history of hormone-sensitive cancers (breast, ovarian, uterine, prostate, colorectal) Anyone with genetic mutations predisposing to cancer (BRCA1/2, Lynch syndrome, etc.) Anyone with active autoimmune disease or severe inflammatory conditions Pregnant or breastfeeding women Anyone who has not established foundational health practices Competitive athletes (most peptides are banned substances) Anyone seeking a "quick fix" rather than commitment to comprehensive health optimization If Considering Peptides: A Cautious Approach For patients who have established solid foundations, have no contraindications, understand the limitations of current evidence, and wish to explore peptides as a potential adjunct, here is the approach I might considerwith significant caveats: Lower-Risk Starting Point Topical GHK-Cu: This has the most established safety profile and documented benefits for skin health
GHRP-2 acts rapidly, while Sermorelin supports the foundational release mechanism
Usage Cited in: Chem Biol Interact
